GLENMARK PHARMACEUTICALS
Back to Cashflow Statement
|
GLENMARK PHARMACEUTICALS Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹-2,709 Cr | ₹787 Cr | ₹-3,906 Cr | ₹-77 Cr | ₹-520 Cr |
What is the latest Cash Flow from Financing Activities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2026 | ₹-2,709 Cr |
| Mar2025 | ₹787 Cr |
| Mar2024 | ₹-3,906 Cr |
| Mar2023 | ₹-77 Cr |
| Mar2022 | ₹-520 Cr |
How is Cash Flow from Financing Activities of GLENMARK PHARMACEUTICALS Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2026 | ₹-2,709 Cr | Negative | |
| Mar2025 | ₹787 Cr | Positive | |
| Mar2024 | ₹-3,906 Cr | Negative | |
| Mar2023 | ₹-77 Cr | Negative | |
| Mar2022 | ₹-520 Cr | - | |
Compare Cash Flow from Financing Activities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹65,137.4 Cr | 1.6% | 3.1% | 13.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹450,211.0 Cr | -3% | -4.1% | 16.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹228,303.0 Cr | 0.6% | 17.5% | 41.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹189,233.0 Cr | 1.7% | -0.6% | 35.5% | Stock Analytics | |
| CIPLA | ₹115,672.0 Cr | -2% | -0.7% | -4.9% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹98,533.5 Cr | -1.5% | -3.5% | -2.2% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 1.6% |
3.1% |
13.6% |
| SENSEX | -1.2% |
-1.2% |
-3.3% |
You may also like the below Video Courses